Skip to main content
SpringerLink
Log in

Vom Mutterkorn zum selektiven Serotoninrezeptoragonisten — Historische Aspekte der Entwicklung eines spezifischen Migränetherapeutikums

  • Chapter
Migräne

  • 40 Accesses

Zusammenfassung

Verfolgt man die historische Entwicklung der Migränebehandlung über die Jahrtausende hinweg, lassen sich die ganz unterschiedlichen empfohlenen Therapiestrategien meist als Ausdruck der jeweils vorherrschenden Vorstellung der Krankheitsursache nachvollziehen. Änderte sich diese Sichtweise hatte das häufig auch Einfluß auf die Behandlung [55]. Einige Maßnahmen allerdings überdauerten auch manchmal einen zwischenzeitlichen Hypothesenwandel, weil sich in der Praxis unabhängig von jedem theoretischen Überbau ihre — wie auch immer zu erklärende — Wirksamkeit erwiesen hat [55].

In Dankbarkeit gewidmet meiner lieben Mutter, Frau Dr. med. dent. Klara Katharina Ensink, zu ihrem 70. Geburtstag, für die ich — zu meinem Bedauern — erst in den letzten Jahren über ein effektives Therapeutikum zur Linderung ihrer Migräne verfügte, als die Attacken bereits spontan seltener und weniger intensiv auftraten. Das über Jahrzehnte zu Hause miterlebte Leiden hat mich nachhaltig für dieses Forschungsgebiet interessiert und für die Beschwerden von Migränepatienten sensibilisiert.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 64.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 84.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Abulcasis(1861) La chirurgie d’Albucasis. - Traduite par le Dr. Lucien Leclere. Baillière, Paris (zit. nach [211])

    Google Scholar 

  2. Aellig WH (1967) Periphere Kreislaufwirkungen von Ergotamin, Dihydroergotamin und 1-Methyl-ergotamin an der innervierten, perfundierten Hinterextremität des Hundes. Helv Physiol Pharmacol Acta 25: 374–396

    PubMed  CAS  Google Scholar 

  3. Aeilig WH (1974) Venoconstrictor effect of dihydroergotamine in superficial hand veins. Eur J Clin Pharmacol 7: 137–139

    Article  Google Scholar 

  4. Aellig WH (1975) Untersuchungen über die venenkonstringierende Wirkung von Ergotverbindungen am Menschen. Triangel 14: 39–46

    CAS  Google Scholar 

  5. Aellig WG, Berde B (1969) Studies of the effect of natural and synthetic polypeptide type ergot compounds on a peripheral vascular bed. Br J Pharmacol 36: 561–570

    PubMed  CAS  Google Scholar 

  6. Andrade R, Chaput Y (1991) 5-Hydroxytryptamine4-like receptors mediate the slow excitatory response to serotonin in the rat hippocampus. J Pharmacol Exp Ther 257/3: 930–937

    PubMed  CAS  Google Scholar 

  7. Anonym(1771) Of the head-ache. In: Encyclopaedia Britannica; or a dictionary of arts and sciences, compiled upon a new plan. In which the different sciences and arts are digested into distinct treatises or systems; and the various technical terms, etc. are explained as they occur in the order of the alphabet. A Bell and C Macfarquhar, Edinburgh

    Google Scholar 

  8. Anthony M, Lance JW (1971) Histamine and serotonin in cluster headache. Arch Neurol 25: 225–231

    Article  PubMed  CAS  Google Scholar 

  9. Anthony M, Lance JW (1989) Plasma serotonin in patients with chronic tension headaches. J Neurol Neurosurg Psychiatry 52: 182–184

    Article  PubMed  CAS  Google Scholar 

  10. Anthony M, Hinterberger H, Lance JW (1967) Plasma serotonin in migraine and stress. Arch Neurol 16: 544–552

    Article  PubMed  CAS  Google Scholar 

  11. Anthony M, Hinterberger H, Lance JW (1969) The possible relationship of serotonin to the migraine syndrome. Res Clin Stud Headache 2: 29–59

    CAS  Google Scholar 

  12. Apelt O (1918) Platons Dialoge Charmides, Lysis, Menexenos (übersetzt und erläutert). Meiner, Leipzig

    Google Scholar 

  13. Aretaeus Cappadox (1856) The extant works of Aretaeus, the cappadocian. - Translated by Francis Adams. Sydenham Society, London

    Google Scholar 

  14. Barger G, Carr FH (1906) Note on ergot alkaloids. Chem News J Phys Sci 94: 89

    Google Scholar 

  15. Barger G, Carr FH (1907) The alkaloids of ergot. J Chem Soc 91: 337–353

    CAS  Google Scholar 

  16. Bastian JM, Ebnöther A, Jucker E, Rissi E, Stoll AP (1966) 4H-Benzo[4,5]cyclo- hepta[l,2-b]thiophene. Helv Chim Acta 49: 214–234

    Article  Google Scholar 

  17. Becker T (1879) Plato’s Charmides - inhaldich eriäutert. CEM Pfeffer, Halle

    Google Scholar 

  18. Bennett JP, Aghajanian GK (1974) D-LSD binding to brain homogenates: possible relationship to serotonin receptors. Life Sci 15: 1935–1944

    Article  CAS  Google Scholar 

  19. Berde B (1972) Recent progress in the elucidation of the mechanism of action of ergot compounds used in migraine therapy. Med J Aust [Special Suppl 2] 59/2: 15–26

    Google Scholar 

  20. Bergouignan M, Seilhean A (1960) La place des anti-sérotonines dans le traitement des migraines et des céphalées vaso-motrices. Presse Med 68: 2176–2178

    Google Scholar 

  21. Biancalana L (1931) Sulla patogenesi e sul trattamento dei disturbi più comuniche seguono la rachianestesia. Minerva Med 22: 393–400

    Google Scholar 

  22. Blumenthal LS, Fuchs M (1952) The use of ergot in the treatment of headache. In: Grumbach AS, Rivkine A (eds) IAA- Premier congrès international d’allergie, First international congress for allergy, Erster internationaler Allergiekongress, Zürich, 23–29 septembre 1951 - Comptes rendus, Proceedings, Kongressbericht. Karger, Basel New York, pp 578–583

    Google Scholar 

  23. Bluntschli HJ, Goetz RH (1947) Ueber Kreislaufwirkungen neuer Mutterkorn-Alkaloide am Menschen. Schweiz Med Wochenschr 77: 769–771

    PubMed  CAS  Google Scholar 

  24. Bluntschli HJ, Goetz RH (1948) The effect of ergot derivatives on the circulation in man with special reference to two new hydrogenated compounds (dihydroergotamine and dihydroergocomine). Am Heart J 35: 873–894

    Article  CAS  Google Scholar 

  25. Bockaert J, Sebben M, Dumuis A (1990) Pharmacolocial characterization of 5- hydroxytryptamine4(5-HT4) receptors positively coupled to adenylate cyclase in adult guinea pig hippocampal membranes: effect of substituted benzamide derivatives. Mol Pharmacol 37: 408–411

    PubMed  CAS  Google Scholar 

  26. Boddeke HWGM, Kalkman HO (1990) Zacopride and BRL 24924 induce an increase in EEG-energy in rats. Br J Pharmacol 101: 281–284

    PubMed  CAS  Google Scholar 

  27. Bradley PB, Engel G, Feniuk W, Fozard JR, Humphrey PPA, Middlemiss DN, Mylecharane EJ, Richardson BP, Saxena PR (1986) Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacology 25: 563–576

    Article  PubMed  CAS  Google Scholar 

  28. Brock S, O’Sullivan M, Young D (1934) The effect of non-sedative drugs and other measures in migraine. Am J Med Sci (New Series) 188: 253–260

    Google Scholar 

  29. Brodie TG (1900–1901) The immediate action of an intravenous injection of blood- serum. J Physiol (Lond) 26: 48–71

    CAS  Google Scholar 

  30. Brodie TG (1903) The perfusion of surviving organs. J Physiol (Lond) 29: 266–275

    CAS  Google Scholar 

  31. Buzzi MG, Moskowitz MA (1989) GR43175, a 5-HT1-like agonist, blocks neurogenic plasma protein extravasation in dura mater. Cephalalgia 9 [Suppl 10]: 27–28

    Google Scholar 

  32. Buzzi MG, Moskowitz MA (1990) The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater. Br J Pharmacol 99: 202–206

    PubMed  CAS  Google Scholar 

  33. Cerletti A, Rothlin E (1955) Role of 5-hydroxytryptamine in mental diseases and its antagonism to lysergic acid derivates. Nature 176: 785–786

    Article  PubMed  CAS  Google Scholar 

  34. Cerletti A, Doepfner W (1958) Spezifische Steigerung der serotonin-antagonistischen Wirkung von Lysergsäurederivaten durch Methylierung des Indolstickstoffes der Lysergsäure. Helv Physiol Pharmacol Acta 16: C55-C57

    Google Scholar 

  35. Chapuis JP (1948) Migraines, céphalées et sympathiocolytiques. Schweiz Med Wochenschr 78: 1125–1127

    PubMed  CAS  Google Scholar 

  36. Clarke DE, Craig DA, Fozard JR (1989) The 5-HT4 receptor: naughty, but nice. Trends Pharmacol Sci 10: 385–386

    Article  PubMed  CAS  Google Scholar 

  37. Cohen SG, Criep LH (1949) Observations on the symptomatic treatment of chronic vascular headache with cafergone (ergotamine tartrate and caffeine). N Engl J Med 241: 896–900

    Article  PubMed  CAS  Google Scholar 

  38. Connor HE, Feniuk W, Humphrey PPA (1989) Characterization of 5-HT receptors mediating contracting of canine and primate basilar artery by use of GR43175, a selective 5-HT1-like receptor agonist. Br J Pharmacol 96: 379–387

    PubMed  CAS  Google Scholar 

  39. Connor HE, Feniuk W, Lloyd K, Humphrey PPA (1992) Migraine, serotonin and sumatriptan. Vase Med Rev 3: 115–128

    Google Scholar 

  40. Craig DA, Clarke DE (1990) Pharmacological characterization of a neuronal receptor for 5-hyroxytryptamine in guinea pig ileum with properties similar to the 5-hydroxytryptamine4 receptor. J Pharmacol Exp Ther 252/3: 1378–1386, Eratum 253/2:1

    PubMed  CAS  Google Scholar 

  41. Craig DA, Eglen RM, Walsh LKM, Perkins LA, Whiting RL, Clarke DE (1990) 5-Methoxytryptamine and 2-methy 1–5-hydroxytryptamine-induced desensitization as a discriminative tool for the 5-HT3 and putative 5-HT4 receptors in guinea pig ileum. Naunyn Schmiedebergs Arch Pharmacol 342: 9–16

    CAS  Google Scholar 

  42. Critchely M (1967) Migraine: From Cappadocia to Queen Square. In: Smith R (ed) Background to migraine. - First Migraine Symposium, 8th-9th November 1966. Heinemann Medical, London, pp 28–38

    Google Scholar 

  43. Curran DA, Hinterberger H, Lance JW (1965) Total plasma serotonin, 5-hydroxyin- doleacetic acid and p-hydroxy-m-methoxy-mandelic acid excretion in normal and migrainous subjects. Brain 88: 997–1010

    Article  PubMed  CAS  Google Scholar 

  44. Curzon G, Theaker P, Phillips B (1966) Excretion of 5-hydroxyindolyl acetic acid (5HIAA) in migraine. J Neurol Neurosurg Psychiatry 29: 85–90

    Article  PubMed  CAS  Google Scholar 

  45. Dale HH (1906) On some physiological actions of ergot. J Physiol (Lond) 34: 163–206

    Google Scholar 

  46. Dalsgaard-Nielsen T (1960) Ueber die prophylaktische Behandlung der Migräne mit Deseril. Praxis 49: 867–868

    PubMed  CAS  Google Scholar 

  47. Dimitriadou V, Buzzi MG, Theoharides TC, Moskowitz MA (1991) Antiinflammatory effects of dihydroergotamine and sumatriptan in blood vessels and mast cells of dura mater. Cephalalgia 11 [Suppl 11]: 9–10

    Google Scholar 

  48. Doepfner W, Cerletti A (1958) Comparison of lysergic acid derivatives and antihistamines as inhibitors of the edema provoked in the rat’s paw by serotonin. Int Arch Allergy 12: 89–97

    Article  PubMed  CAS  Google Scholar 

  49. Drummond PD, Lance JW (1983) Extracranial vascular changes and the source of pain in migraine headache. Ann Neurol 13: 32–37

    Article  PubMed  CAS  Google Scholar 

  50. Dumuis A, Bouhelal R, Sebben M, Bockaert J (1988) A 5-HT receptor in the central nervous system, positively coupled with adenylate cyclase, is antagonized by ICS 205 930. Eur J Pharmacol 146: 187–188

    Article  PubMed  CAS  Google Scholar 

  51. Dumuis A, Bouhelal R, Sebben M, Cory R, Bockaert J (1988) A nonclassical 5-hydroxytryptamine receptor positively coupled with adenylte cyclase in the central nervous system. Mol Pharmacol 34: 880–887

    PubMed  CAS  Google Scholar 

  52. Dumuis A, Sebben M, Bockaert J (1989) BRL 24924: a potent agonist at a non- classical 5-HT receptor positively coupled with adenylte cyclase in colliculi neurons. Eur J Pharmacol 162: 381–384

    Article  PubMed  CAS  Google Scholar 

  53. Dumuis A, Sebben M, Bockaert J (1989) The gastrointestinal prokinetic benzamide derivatives are agonists at the non-classical 5-HT receptor (5-HT4) positively coupled to adenylate cyclase in neurons. Naunyn Schmiedebergs Arch Pharmacol 340: 403–410

    Article  PubMed  CAS  Google Scholar 

  54. Dvilansky A, Rishpon S, Nathan I, Zolotow Z, Korczyn AD (1976) Release of platelet 5-hydroxytryptamine by plasma taken from patients during and between migraine attacks. Pain 2: 315–318

    Article  PubMed  CAS  Google Scholar 

  55. Edmeads J (1991) The treatment of headache: a historical perspective. In: Gallagher RM (ed) Drug therapy for headache. Dekker, New York Basel Hong Kong, pp 1–8

    Google Scholar 

  56. Edvinsson L, Jansen I, Olesen J (1991) Analysis of the vasoconstrictor effects of sumatriptan on human cranial arteries. Cephalalgia 11 [Suppl 11]: 210–211

    Google Scholar 

  57. Eglen RM, Swank SR, Walsh LKM, Whiting RL (1990) Characterization of 5-HT3 and „atypical“ 5-HT receptors mediating guinea-pig ileal contractions in vitro. Br J Pharmacol 101: 513–520

    PubMed  CAS  Google Scholar 

  58. Ekbom K (1968) Nitroglycerin as a provocative agent in cluster headache. Arch Neurol 19: 487–493

    Article  PubMed  CAS  Google Scholar 

  59. Elswood CJ, Bunce KT, Humphrey PPA (1991) Identification of putative 5-HT4 receptors in guinea-pig ascending colon. Eur J Pharmacol 196: 149–155

    Article  PubMed  CAS  Google Scholar 

  60. Erspamer V (1966) Occurrence of indolealkylamines in nature. In: Eichler O, Farah A (Hrsg) Handbuch der experimentellen Pharmakologie; Vol 19 (NF): Erspamer V (Hrsg) 5-Hydroxytryptamine and related indolealkylamines. Springer, Berlin Heidelberg New York, S 132–181

    Google Scholar 

  61. Erspamer V, Asero B (1952) Identification of enteramine, the specific hormone of the enterochromaffin cell system, as 5-hydroxytryptamine. Nature 169: 800–801

    Article  PubMed  CAS  Google Scholar 

  62. Eulenburg A (1883) Subcutane Injectionen von Ergotonin- (Tanret) = Ergotinium citricum solutum (Gehe). Dtsch Med Wochenschr 9: 637–639

    Google Scholar 

  63. Fanchamps A (1974) The role of humoral mediators in migraine headache. Can J Neurol Sci 1: 189–195

    PubMed  CAS  Google Scholar 

  64. Fanchamps A (1977) 50 Jahre Sandoz-Engagement in der Migränetherapie. Triangel 15: 103–111

    Google Scholar 

  65. Fanchamps A, Doepfner W, Weidmann H, Cerletti A (1960) Pharmakologische Charakterisierung von Deseril, einem Serotonin-Antagonisten. Schweiz Med Wochenschr 90: 1040–1046

    PubMed  CAS  Google Scholar 

  66. Feldberg W, Toh CC (1953) Distribution of 5-hydroxytryptamine (serotonin, enteramin) in the wall of the digestive tract. J Physiol (Lond) 119: 352–362

    CAS  Google Scholar 

  67. Feniuk W, Humphrey PPA, Perren MJ (1989) The selective carotid arterial vasoconstrictor action of GR 43175 in anaesthetized dogs. Br J Pharmacol 96: 83–90

    PubMed  CAS  Google Scholar 

  68. Feniuk W, Humphrey PPA, Perren MJ (1989) GR 43175 does not share the complex pharmacology of the ergots. Cephalagia 9 (Suppl 9): 35–39

    Google Scholar 

  69. Ferrari MD, Frölich M, Odink J, Tapparelli C, Portielje JEA, Bruyn GW (1987) Methionine-enkephalin and serotonin in migraine and tension headache. In: Clifford Rose F (ed) Advances in headache research - Proceedings of the 6th international migraine symposium. Libbey, London, pp 227–234

    Google Scholar 

  70. Fordyce J (1758) Historia febris miliaris, et de hemicrania dissertatio. Wilson & Durham, London

    Google Scholar 

  71. Fothergill J (1784) Remarks on that complaint commonly known under the name of the sick headach. Med Obs Inq Soc Physicians (Lond) 6: 103–137

    Google Scholar 

  72. Fozard JR (1982) Serotonin, migraine and platelets. Prog Pharmacol 4: 135–146

    CAS  Google Scholar 

  73. Fozard JR (1984) Neuronal 5-HT receptors in the periphery. Neuropharmacology 23: 1473–1486

    Article  PubMed  CAS  Google Scholar 

  74. Fozard JR (1984) MDL 72222: a potent and highly selective antagonist at neuronal 5-hydroxytryptamine receptors. Naunyn Schmiedebergs Arch Pharmacol 326: 36–44

    Article  CAS  Google Scholar 

  75. Friberg L, Olesen J, Iversen HK, Sperling B (1991) Migraine pain associated with middle cerebral artery dilatation: reversal by sumatriptan. Lancet 338: 13–17

    Article  PubMed  CAS  Google Scholar 

  76. Friedman AP (1960) Evaluation of nonnarcotic chemical agents in headaches. Ann NY Acad Sci 86: 216–225

    Article  PubMed  CAS  Google Scholar 

  77. Friedman AP (1972) The headache in history, literature, and legend. Bull NY Acad Med 48: 661–681

    CAS  Google Scholar 

  78. Friedman AP, Brenner C (1948) Treatment of the migraine attack. Am Pract 2: 467–470

    CAS  Google Scholar 

  79. Friedman AP, Storch TJC von (1951) Recent advances in treatment of migraine. JAMA 145: 1325–1329

    Article  CAS  Google Scholar 

  80. Friedman AP, Brazil P, Storch TJC von (1955) Ergotamine tolerance in patients with migraine. JAMA 157: 881–884

    Article  CAS  Google Scholar 

  81. Friedman AP, Storch TJC von, Araki S (1959) Ergotamine tartrate: its history, action, and proper use in the treatment of migraine. NY State J Med 59: 2359–2366

    CAS  Google Scholar 

  82. Friedman MD, Friedman DA (1945) Dihydroergotamine (D.H.E. 45) in the treatment of migraine: preliminary clinical observations. Ohio State Med J 41: 1099- 1100

    CAS  Google Scholar 

  83. Fuchs M, Blumenthal LS (1950) Use of ergot preparations in migraine. JAMA 143: 1462–1464

    Article  CAS  Google Scholar 

  84. Gaddum JH (1953) Tryptamine receptors. J Physiol (Lond) 119: 363–368

    CAS  Google Scholar 

  85. Gaddum JH (1953) Antagonism between lysergic acid diethylamide and 5-hy- droxytryptamine. J Physiol (Lond) 121: 15P

    Google Scholar 

  86. Gaddum JH, Hameed KA (1954) Drugs which antagonize 5-hydroxytryptamine. Br J Pharmacol 9: 240–248

    CAS  Google Scholar 

  87. Gaddum JH, Picarelli ZP (1957) Two kinds of tryptamine receptor. Br J Pharmacol 12: 323–328

    CAS  Google Scholar 

  88. Glover V, Sandler M (1989) Can the vascular and neurogenic theories of migraine finally be reconciled? Trends Pharmacol Sci 10: 1–3

    Article  PubMed  CAS  Google Scholar 

  89. Goadsby PJ, Gundlach AL (1991) Localizaton of 3H-dihydroergotamine-binding sites in the cat central nervous system: relevance to migraine. Ann Neurol 29: 91–94

    Article  PubMed  CAS  Google Scholar 

  90. Goadsby PJ, Piper RD, Lambert GA, Lance JW (1985) Effect of stimulation of nucleus raphe dorsalis on carodd blood flow. - I. The monkey. Am J Physiol 248: R257-R262

    PubMed  CAS  Google Scholar 

  91. Goadsby PJ, Piper RD, Lambert GA, Lance JW (1985) Effect of stimulation of nucleus raphe dorsalis on carotid blood flow. - II. The cat. Am J Physiol 248: R263-R269

    PubMed  CAS  Google Scholar 

  92. Gozlan H, Ei Mestikawy S, Pichat L, Glowinsky J, Hamon M (1983) Identification of presynaptic serotonin autoreceptors using a new ligand: 3H-PAT. Nature 305: 140–142

    Article  PubMed  CAS  Google Scholar 

  93. Graham JR (1960) Use of a new compound, UML-491 (I-methyl-D-lysergic acid butanolamide), in the prevention of various types of headache. N Engl J Med 263: 1273–1277

    Article  PubMed  CAS  Google Scholar 

  94. Graham JR (1965) Possible renal complications of Sansert (methysergide) therapy for headache. Headache 5: 12–14

    Article  PubMed  CAS  Google Scholar 

  95. Graham JR, Wolff HG (1938) Mechanism of migraine headache and action of ergotamine tartrate. Arch Neurol Psychiatry 39: 737–763

    CAS  Google Scholar 

  96. Gwinn RP, Norton PB, Goetz PW (eds) (1991) The new Encyclopaedia Britannica (Vol 21). Encyclopaedia Britannica, Chicago Auckland Geneva London Madrid Manila Paris Rome Seoul Sydney Tokyo Toronto

    Google Scholar 

  97. Hamlin KE, Fischer FE (1951) The synthesis of 5-hydroxytryptamine. J Am Chem Soc 73: 5007–5008

    Article  CAS  Google Scholar 

  98. Hansel FK (1949) The treatment of headache - with particular reference to the use of Cafergone (ergotamine tartrate and caffeine) for the relief of attacks. Ann Allergy 7: 155–161

    PubMed  CAS  Google Scholar 

  99. Hardebo JE, Suzuki N, Ekman R (1989) Morphological and functional substrates for neurogenic inflammation in the human internal carotid artery. - Implication for cluster headache. Cephalalgia 9 [Suppl 10]: 17–18

    Google Scholar 

  100. Hartman MM (1945) Parenteral use of dihydroergotamine in migraine. Ann Allergy 3: 440–442

    PubMed  CAS  Google Scholar 

  101. Hetényi G (1944) Ueber die Migräne-Krankheit. Praxis 33: 321–325

    Google Scholar 

  102. Heuring RE, Peroutka SJ (1987) Characterization of a novel 3H-5-hy- droxytryptamine binding site subtype in bovine brain membranes. J Neurosci 7: 894–904

    PubMed  CAS  Google Scholar 

  103. Heyck H (1960) Serotoninantagonisten in der Behandlung der Migräne und der Erythroprosopalgie Bings oder des Horton-Syndroms. Schweiz Med Wochenschr 90: 203–209

    PubMed  CAS  Google Scholar 

  104. Hofmann A (1964) Die Mutterkomalkaloide. Enke, Stuttgart

    Google Scholar 

  105. Horton BT, Peters GA, Blumenthal LS (1945) A new product in the treatment of migraine: a preliminary report. Proc Mayo Clin 20: 241–248

    Google Scholar 

  106. Horton BT, Ryan R, Reynolds JL (1948) Clinical observation on the use of E. C. 110, a new agent for the treatment of headache. Proc Mayo Clin 23: 105–108

    PubMed  CAS  Google Scholar 

  107. Hoyer D (1988) Functional correlates of serotonin 5-HTi recognition sites. J Recept Res 8: 59–81

    PubMed  CAS  Google Scholar 

  108. Hoyer D (1990) Serotonin 5-HT3, 5-HT4 and 5-HT-M receptors. Neuropsycho- pharmacology 3: 371–383

    CAS  Google Scholar 

  109. Hude C (Hrsg) (1923) Aretaeus. Teubner, Leipzig Berlin

    Google Scholar 

  110. Humphrey PPA (1991) 5-Hydroxytryptamine and the pathophysiology of migraine. J Neurol 238 [Suppl 1]: S38-S44

    Article  PubMed  Google Scholar 

  111. Humphrey PPA, Feniuk W (1991) Mode of action of the antimigraine drug sumatriptan. Trends Pharmacol Sci 12: 444–446

    Article  PubMed  CAS  Google Scholar 

  112. Humphrey PPA, Feniuk W, Perren MJ, Connor HE, Oxford AW, Coates JH, Butina D (1988) GR43175, a selective agonist for the 5-HTi-like receptor in dog isolated saphenous vein. Br J Pharmacol 94: 1123–1132

    PubMed  CAS  Google Scholar 

  113. Humphrey PPA, Feniuk W, Perren MJ, Connor HE, Oxford AW (1989) The pharmacology of the novel 5-HT1-like receptor agonist, GR 43175. Cephalalgia 9 [Suppl 9]: 23–33

    PubMed  Google Scholar 

  114. Humphrey PPA, Feniuk W, Perren MJ, Oxford AW, BriUain RT (1990) Sumatriptan succinate - GR-43175C. Drugs Future 15: 104–105

    Google Scholar 

  115. Humphrey PPA, Hartig P, Hoyer D (1993) A proposed new nomenclature for 5-HT receptors. Trends Pharmacol Sci 14: 233–236

    Article  PubMed  CAS  Google Scholar 

  116. Humphrey PPA, Feniuk W, Perren MJ, Oxford AW, BriUain RT (1989) Sumatriptan succinate. Drugs Future 14: 35–39

    Google Scholar 

  117. Idres S, Delarue C, Lefebvre H, Vaudry H (1991) Benzamide derivatives provide evidence for the involvement of a 5-HT4 receptor type in the mechanism of action of serotonin in frog adrenocortical cells. Brain Res Mol Brain Res 10: 251–258

    Article  PubMed  CAS  Google Scholar 

  118. Isler H (1965) Thomas Willis. - Ein Wegbereiter der modernen Medizin 1621- 1675. Wissenschafdiche Verlagsgesellschaft, Stuttgart

    Google Scholar 

  119. Isler H (1987) Retrospect: the history of thought about migraine from Aretaeus to 1920. In: Blau JN (ed) Migraine: Clinical, therapeutic, conceptual and research aspects. Chapman & Hall, London, pp 659–674

    Google Scholar 

  120. Joachim H (1890) Papyros Ebers. - Das älteste Buch über Heilkunde. Aus dem Ägyptischen zum ersten Mal vollständig übersetzt. Reimer, Berlin

    Google Scholar 

  121. Jucker E (1963) Einige neuere Entwicklungen in der Chemie der Psychopharmaka. Angew Chem 75: 524–538

    Article  CAS  Google Scholar 

  122. Kassner R (Hrsg) (1920) Piatons Ion, Lysis, Charmides. - Ins Deutsche übertragen. Diederichs, Jena Leipzig, S 75–125

    Google Scholar 

  123. Kaumann AJ (1990) Piglet sinoatrial 5-HT receptors resemble human atrial 5- HT4-like receptors. Naunyn Schmiedebergs Arch Pharmacol 342: 619–622

    Article  PubMed  CAS  Google Scholar 

  124. Kilpatrick GJ, Jones BJ, Tyers MB (1987) Identification and distribudon of 5-HT3 receptors in rat brain using radioligand binding. Nature 330: 746–748

    Article  PubMed  CAS  Google Scholar 

  125. Kimball RW, Friedman AP, Vallejo E (1960) Effect of serotonin in migraine patients. Neurology 10: 107–111

    PubMed  CAS  Google Scholar 

  126. Köcher F (1963) Die babylonisch-assyrische Medizin in Texten und Untersuchungen. Band I: Keilschriften aus Assur 1. De Gruyter, Berlin

    Google Scholar 

  127. Král VA (1948) Neurologische Erfahrungen mit „Dihydroergotamin”. Schweiz Arch Neurol Psychiatr 62: 128–150

    PubMed  Google Scholar 

  128. Kühn CG (Hrsg) (1825) Magni Hippocratis opera omnia. Tomus I. Cnoblochi, Lipsiae

    Google Scholar 

  129. Lance JW (1992) History of involvement of 5-HT in primary headaches. In: Olesen J, Saxene PR (eds) 5-Hydroxytryptamine mechanisms in primary hea- dachs. Raven Press, New York, pp 19–28

    Google Scholar 

  130. Lance JW, Anthony M (1968) Clinical trial of a new serotonin antagonist, BC 105, in the prevendon of migraine. Med J Aust 55: 54—55

    Google Scholar 

  131. Lance JW, Anthony M, Gonski A (1967) Serotonin, the carotid body, and cranial vessels in migraine. Arch Neurol 16: 553–558

    Article  PubMed  CAS  Google Scholar 

  132. Lennox WG (1934) The use of ergotamine tartrate in migraine. N Engl J Med 210: 1061–1065

    Article  Google Scholar 

  133. Lennox WG, Storch TJC von (1935) Experience with ergotamine tartrate in 120 padents with migraine. JAMA 105: 169–171

    Article  CAS  Google Scholar 

  134. Leonhardt S, Herrick-Davies K, Titeler M (1989) Detection of a novel serotonin receptor subtype (5HTIE) in human brain: interaction with a GTP-binding protein. J Neurochem 53: 465–471

    Article  PubMed  CAS  Google Scholar 

  135. Logan AH, Allen EV (1934) The treatment of migraine with ergotamine tartrate. Proc Mayo Clin 9: 585–588

    Google Scholar 

  136. Lonicerus A (1582) Kreuterbuch, künsdiche Conterfeytunge der Bäume, Stauden, Hecken, Kreuter, Getreyde, Gewürtze - von neuwem ersehen, und durchauß an vilen Orten gebessert, auch weit über vorige Edition gemehret. Christian Egenolffs Erben, Franckfort

    Google Scholar 

  137. Ludwig C, Schmidt A (1869) Das Verhalten der Gase, welche mit dem Blut durch den reizbaren Säugethiermuskel strömen. Arb Physiol Anst Leipz 3: 1–61

    Google Scholar 

  138. Lyons AS, Petrucelli RJ (1987) Medicine - An illustrated history. Abradale, New York

    Google Scholar 

  139. Maier HW (1926) L’ergotamine, inhibiteur du sympathique étudié en clinique, comme moyen d’exploration et comme agent thérapeutique. Rev Neurol (Paris) 33/1: 1104–1108

    Google Scholar 

  140. McHenry LC jr (1969) Garrison’s history of neurology. Revised and enlarged with a bibliography of classical, original and standard works in neurology. Thomas, Springfield

    Google Scholar 

  141. Middlemiss DN, Fozard JR (1983) 8-Hydroxy-2-(di-n-propylamino)-tetralin discriminates between subtypes of the 5-HT 1-recognition site. Eur J Pharmacol 90: 151–153

    Article  PubMed  CAS  Google Scholar 

  142. Moister EC, Stanton JR, Freis ED (1949) Observations on the development of tolerance during prolonged oral administration of dihydroergocomine. J Pharmacol Exp Ther 96: 21–30

    PubMed  CAS  Google Scholar 

  143. Möllendorff W (1867) Ueber Hemikranie. Arch Pathol Anat Physiol Klin Med 41: 385–395

    Article  Google Scholar 

  144. Moskowitz MA (1992) Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol Sci 13: 307–311

    Article  PubMed  CAS  Google Scholar 

  145. Moskowitz MA (1993) Neurogenic inflammation in the pathophysiology and treatment of migraine. Neurology 43 [Suppl 3]: S16-S20

    PubMed  CAS  Google Scholar 

  146. Moskowitz MAm, Buzzi MG (1991) Neuroeffector functions of sensory fibres: implications for headache mechanisms and drug actions. J Neurol 238 [Suppl 1]: S18-S22

    Article  PubMed  Google Scholar 

  147. Moskowitz MA, Brody M, Lin-Chen LY (1983) In vitro release of immunoreactive substance P from putative afferent nerve endings in bovine pia arachnoid. Neu- roscience 9: 809–814

    CAS  Google Scholar 

  148. Mück-Seler D, Deanovic Z, Dupelj M (1979) Platelet serotonin (5-HT) and 5-HT releasing factor in plasma of migrainous patients. Headache 19: 14–17

    Article  PubMed  Google Scholar 

  149. Neuhold K, Taeschler M (1963) Über die Rolle des Serotonin bei dem durch intraperitoneale Injektion von Essigsäure ausgelösten Schmerzphänomen bei der Maus. Naunyn Schmiedebergs Arch Pharmacol 245: 130–131

    Google Scholar 

  150. Nieuwenhuys R (1985) Chemoarchitecture of the brain. Springer, Berlin Heidelberg New York Tokyo, pp 33–41

    Book  Google Scholar 

  151. Ostfeld AM (1959) Some aspects of cardiovascular regulations in man. Angiology 10: 34–42

    Article  PubMed  CAS  Google Scholar 

  152. Ostfeld AM (1960) Migraine headache. - Its physiology and biochemistry. JAMA 174: 1188–1190

    Article  PubMed  CAS  Google Scholar 

  153. Ostfeld AM, Chapman LF, Goodell H, Wolff HG (1956) Studies in headache: a summary of evidence implicating a locally active chemical agent in migraine. Trans Am Neurol Assoc 81: 35–36

    Google Scholar 

  154. Ostfeld AM, Chapman LF, Goodell H, Wolff HG (1957) Studies in headache. - Summary of evidence concerning a noxious agent active locally during migraine headache. Psychsom Med 19: 199–208

    CAS  Google Scholar 

  155. O’Sullivan M (1936) Termination of one thousand attacks of migraine with ergotamine tartrate. JAMA 107: 1208–1212

    Article  Google Scholar 

  156. Page IH (1954) Serotonin (5-hydroxytryptamine). Physiol Rev 34: 563–588

    PubMed  CAS  Google Scholar 

  157. Page IH, McCubbin JW (1953) Modification of vascular response to serotonin. Am J Physiol 174: 436–444

    PubMed  CAS  Google Scholar 

  158. Pazos A, Hoyer D, Palacios JM (1985) The binding of serotonergic ligands to the porcine choroid plexus: characterization of a new type of serotonin recognition site. Eur J Pharmacol 106: 539–546

    Article  Google Scholar 

  159. Pazos A, Probst A, Palacios JM (1987) Serotonin receptors in the human brain. III. Autoradiographic mapping of serotonin-1 receptors. Neuroscience 21: 97- 122

    Article  PubMed  CAS  Google Scholar 

  160. Pazos A, Probst A, Palacios JM (1987) Serotonin receptors in the human brain. IV. Autoradiographic mapping of serotonin-2 receptors, neuroscience 21: 123- 139

    CAS  Google Scholar 

  161. Pedigo NW, Yamamura HI, Nelson DL (1981) Discrimination of multiple [3H]5- hydroxytryptamine binding sites by the neuroleptic spiperone in rat brain. J Neurochem 36: 220–226

    Article  PubMed  CAS  Google Scholar 

  162. Peroutka SJ, Snyder SH (1979)Multiple serotonin receptors: differential binding of [3H] 5-hydroxy try ptamine, [3H]lysergic acid diethylamide and [3H] spiroperidol. Mol Pharmacol 16: 687–699

    Google Scholar 

  163. Pollock LA (1946) Dihydroergotamine (D.H.E. 45), a new and effective drug in the treatment of migraine. Rocky Mt Med J 43: 895–897

    CAS  Google Scholar 

  164. Rapport MM (1949) Serum vasoconstrictor (Serotonin) - V. The presence of creatinine in the complex. A proposed structure of the vasoconstrictor principle. J Biol Chem 180: 961–969

    PubMed  CAS  Google Scholar 

  165. Rapport MM (1990) Serotonin research: historical overview. In: Paoletti R, Van houtte PM, Brunello N, Maggi FM (eds) Serotonin: from cell biology to pharmacology and therapeutics. Kluwer Academic, Dordrecht Boston London, pp 1–4

    Google Scholar 

  166. Rapport MM, Koelle GB (1953) The action of antihistaminics and atropine in blocking the spasmogenic activity of serotonin on the guinea pig ileum. Arch Int Pharmacodyn Ther 92: 464–470

    PubMed  CAS  Google Scholar 

  167. Rapport MM, Green AA, Page IH (1947) Purification of the substance which is responsible for the vasoconstrictor acdvity of serum. Fed Proc 6: 184

    PubMed  CAS  Google Scholar 

  168. Rapport MM, Green AA, Page IH (1948) Crystalline serotonin. Science 108: 329–330

    Article  PubMed  CAS  Google Scholar 

  169. Rapport MM, Green AA, Page IH (1948) Partial purification of the vasoconstrictor in beef serum. J Biol Chem 174: 735–741

    PubMed  CAS  Google Scholar 

  170. Rapport MM, Green AA, Page IH (1948) Serum vasoconstrictor (serotonin) - IV. Isolation and characterization. J Biol Chem 176: 1243–1251

    PubMed  CAS  Google Scholar 

  171. Richardson BP, Engel G, Donatsch P, Stadler PA (1985) Identification of serotonin M-receptor subtypes and their specific blockade by a new class of drugs. Nature 316: 126–131

    Article  PubMed  CAS  Google Scholar 

  172. Riley HA (1932) Migraine. Bull Neurol Inst NY 2: 429–544

    Google Scholar 

  173. Rocha e Silva M, Valle JR, Picarelli ZP (1953) A pharmacological analysis of the mode of action of serotonin (5-hydroxytryptamine) upon the guinea-pig ileum. Br J Pharmacol 9: 370–388

    Google Scholar 

  174. Rolf LH, Wiele G, Brune GG (1981) 5-Hydroxytryptamine in platelets of patients with muscle contraction headache. Headache 21: 10–11

    Article  PubMed  CAS  Google Scholar 

  175. Rothlin E (1925) Über die pharmakologische und therapeutische Wirkung des Ergotamins auf den Sympathicus. Klin Wochenschr 4: 1437–1443

    Article  CAS  Google Scholar 

  176. Rothlin E (1926) Contribution à la méthode chimique d’exploraüon du système sympathique. Rev Neurol (Paris) 33/1: 1108–1113

    Google Scholar 

  177. Rothlin E (1944) Zur Pharmakologie der hydrierten natürlichen Mutterkornalkaloide. Helv Physiol Pharmacol Acta 2: C48-C49

    CAS  Google Scholar 

  178. Rothin E (1946) Zur Pharmakologie des Sympathicolydcums Dihydroergotamin DHE 45. Schweiz Med Wochenschr 76: 1254–1259

    Google Scholar 

  179. Rothlin E (1947) The pharmacology of the natural and dihydrogenated alkaloids of ergot. Bull Schweiz Akad Med Wiss 2: 249–273

    CAS  Google Scholar 

  180. Rothlin E (1955) Historical development of the ergot therapy of migraine. Int Arch Allergy 7: 205–209

    Article  PubMed  CAS  Google Scholar 

  181. Ryan RE (1968) Double-blind crossover comparison of BC-105, methysergide and placebo in the prophylaxis of migraine headache. Headache 8: 118–126

    Article  PubMed  CAS  Google Scholar 

  182. Saper JR (1978) Migraine. -1. Classification and pathogenesis. JAMA 239: 2380–2383

    Article  PubMed  CAS  Google Scholar 

  183. Saxena PR (1986) Nature of the 5-hydroxytryptamine receptors in mammalian heart. Prog Pharmacol 6: 173–185

    CAS  Google Scholar 

  184. Saxena PR (1992) Historical aspects of 5-hydroxytryptamine: discovery and receptor classification. In: Olesen J, Saxene PR (eds) 5-Hydroxytryptamine mechanisms in primary headaches. Raven, New York, pp 3–18

    Google Scholar 

  185. Shukla R, Shanker K, Nag D, Verma M, Bhargava KP (1987) Serotonin in tension headache. J Neurol Neurosurg Pychiatry 50: 1682–1684

    Article  CAS  Google Scholar 

  186. Sicuteri F (1959) Prophylactic and therapeutic properties of 1-methyl-lysergic acid butanolamide in migraine - preliminary report. Int Arch Allergy 15: 300–307

    Article  PubMed  CAS  Google Scholar 

  187. Sicuteri F (1967) Vasoneuroactive substances of their implication in vascular pain. Res Clin Stud Headache 1: 6–45

    CAS  Google Scholar 

  188. Sicuteri F, Testi A, Anselmi B (1961) Biochemical invesdgations in headache: increase in the hydroxyindoleacetic acid excretion during migraine attacks. Int Arch Allergy 19: 55–58

    Article  CAS  Google Scholar 

  189. Sicuteri F, Fanciullacci M, Franchi G, Del Bianco PL (1965) Serotonin - bra- dykinin potendation on the pain receptors in man. Life Sci 4: 309–316

    Article  PubMed  CAS  Google Scholar 

  190. Sicuteri F, Franchi G, Del Bianco PL, Anselmi B (1966) Antagonismo sulla 5-HT sulla istamina e sulla acetilcolina di un antiaminico nell’uomo. Sua efficacia nella emicrania. Boll Soc Ital Biol Sper 42: 1097–1100

    CAS  Google Scholar 

  191. Sicuteri F, Franchi G, Del Bianco PL (1967) An antaminic drug, BC 105, in the prophylaxis of migraine. Int Arch Allergy 31: 78–93

    Article  PubMed  CAS  Google Scholar 

  192. Sjaastad O (1975) The significance of blood serotonin levels in migraine. - A critical review. Acta Neurol Skand 51: 200–210

    Article  CAS  Google Scholar 

  193. Speeter ME, Heinzelmann RV, Weisblat DI (1951) The synthesis of the blood serum vasoconstrictor principle serotonin creatinine sulfate. J Am Chem Soc 73: 5514–5515

    Article  CAS  Google Scholar 

  194. Spira PJ, Mylecharane EJ, Lance JW (1976) The effects of humoral agents and antimigraine drugs on the cranial circulation of the monkey. Res Clin Stud Headache 4: 37–75

    PubMed  CAS  Google Scholar 

  195. Spira PJ, Mylecharane EJ, Misbach J, Duckworth JW, Lance JW (1978) Internal and external carotid vascular responses to vasoactive agents in the monkey. Neurology 28: 162–173

    PubMed  CAS  Google Scholar 

  196. Spühler O (1946) Dihydroergotamin (DHE 45) als Sympathicolyticum in der inneren Medizin. Schweiz Med Wochenschr 76: 1259–1263

    Google Scholar 

  197. Stevens LT, Lee FS (1884/87) The action of intermittent pressure and of defi- brinated blood upon the blood vessels of the frog and the terrapin. Stud Biol Lab Johns Hopkins Univ 3: 99–119

    Google Scholar 

  198. Stolla A (1920) Zur Kenntnis der Mutterkomalkaloide. Verh Schweiz Naturforsch Ges 190–191

    Google Scholar 

  199. Stolla A (1947) Lysergsäure-diäthylamid, ein Phantastikum aus der Mutterkom- gruppe. Schweiz Arch Neurol Psychiatr 60: 279–323

    Google Scholar 

  200. Stoll A, Hofmann A (1943) Partialsynthese von Alkaloiden vom Typus des ER- gobasins. Helv Chim Acta 26: 944–965

    Article  CAS  Google Scholar 

  201. Stoll A, Hofmann A (1943) Die Alkaloide der Ergotoxingruppe: Ergocristin, Er- gokryptin und Ergocomin. Helv Chim Acta 26: 1570–1601

    Google Scholar 

  202. Stoll A, Hofmann A (1943) Die Dihydroderivate der natürlichen linksdrehenden Mutterkomalkaloide. Helv Chim Acta 26: 2070–2081

    Article  CAS  Google Scholar 

  203. Stoll A, Hofmann A, Becker B (1943) Die Spaltstücke von Ergocristin, Ergo- kryptin und Ergocomin. Helv Chim Acta 26: 1602–1613

    Article  CAS  Google Scholar 

  204. Storch TJC von (1937) Über die Behandlung des Migräneanfalls mit Ergotamintartrat (Gynergen). Nervenarzt 10: 469–474

    Google Scholar 

  205. Storch TJC von (1938) Complications following the use of ergotamine tartrate. - Their relation to the treatment of migraine headache. JAMA 111: 293–300

    Article  Google Scholar 

  206. Suby HI, Kerr WS, Graham JR, Fraley E (1965) Retroperitoneal fibrosis: a missing link in the chain. J Urol 93: 144–152

    PubMed  CAS  Google Scholar 

  207. Sugden D (1990) 5-Hydroxytryptamine amplifies ß-adrenergic stimulation of N- acetyltransferase activity in rat pinealocytes. J Neurochem 55: 1655–1658

    Article  PubMed  CAS  Google Scholar 

  208. Sumner MJ, Humphrey PPA (1989) Heterogeneous 5-HT 1D binding sites in porcine brain can be differentiated by GR43175. Br J Pharmacol 97 (Proc Suppl): 410P

    Google Scholar 

  209. Sumner MJ, Humphrey PPA (1989) 5-HT 1D binding sites in porcine brain can be sub-divided by GR43175. Br J Pharmacol 98: 29–31

    PubMed  CAS  Google Scholar 

  210. Tanret C (1875) Sur la présence d’un nouvel alcaloide, I’ergotinine, dans le seigle ergoté. C R Acad Sci Paris 81: 896–897

    Google Scholar 

  211. Thomas L (1887) La migraine. A Delahaye et E Lecrosnier, Paris

    Google Scholar 

  212. Thomson WH (1894) Ergot in the treatment of periodic neuralgias. J Nerv Ment Dis (New Series) 19: 124–126

    Google Scholar 

  213. Thorwald J (1962) Macht und Geheimnis der frühen Ärzte - Ägypten, Babylonien, Indien, China, Mexiko, Peru. Droemersche und Thames & Hudson, München Zürich London

    Google Scholar 

  214. Tissot (SAAD) (1778–1783) Traité des nerfs et de leurs maladies. 3 Bde. Didot le jeune, Paris Lausanne

    Google Scholar 

  215. Tissot (SAAD) (1782) Abhandlung über die Nerven und deren Krankheiten, des dritten Bandes zweyter Theil. Deutsch herausgegeben von Joh. Christ. Gotdieb Ackermann. Jacobäer, Leipzig

    Google Scholar 

  216. Trautmann E (1928) Die Beeinflussung migräneartiger Zustände durch ein sympathikushemmendes Mittel (Gynergen). Münch Med Wochenschr 75: 512

    Google Scholar 

  217. Troxler F, Hofmann A (1957) Substitutionen am Ringsystem der Lysergsäure. III. Halogenierung. Helv Chim Acta 40: 2160–2170

    Article  CAS  Google Scholar 

  218. Tzanck A (1928) Le traitement des migraines par le tartrate d’ergotamine. Bull Mem Soc Med Hop Paris 52: 1057–1061

    Google Scholar 

  219. Tzanck A (1929) Le tartrate d’ergotamine dans le traitement des migraines. Bull Mem Soc Med Hop Paris 53: 495–497

    Google Scholar 

  220. Utz DC, Rooke ED, Spittell JA jr, Bartholomew LG (1965) Retroperitoneal fibrosis in patients taking methysergide. JAMA 191: 983–985

    Article  PubMed  CAS  Google Scholar 

  221. Vauquelin M (1816) Analyse du seigle ergoté du bois de Boulogne, près Paris. Ann Chim Phys 3: 337–349

    Google Scholar 

  222. Venzmer G (1977) 5000 Jahre Medizin. - Von vorgeschichtlicher Heilkunde zum ärztlichen Computer. Goldmann, München

    Google Scholar 

  223. Villalón CM, den Boer MO, Heiligers JPC, Saxena PR (1990) Mediaüon of 5-hydroxytryptamine-induced tachycardia in the pig by the putadve 5-HT 4 receptor. Br J Pharmacol 100: 665–667

    PubMed  Google Scholar 

  224. Villalón CM, den Boer MO, Heiligers JPC, Saxena PR (1991) Further charac- terizadon, by use of tryptamine and benzamide derivadves, of the putadve 5-HT4 receptor mediating tachycardia in the pig. Br J Pharmacol 102: 107–112

    PubMed  Google Scholar 

  225. Vriend HJ de (ed) (1984) The old English herbarium and medicina de quadru- pedibus. Oxford Univ. Press, London New York Toronto

    Google Scholar 

  226. Wahl G (1991) Krankheit im halben Kopf. Start 10/4: 16–18

    Google Scholar 

  227. Waeber C, Died MM, Hoyer D, Palacios JM (1989) 5-HT1 receptors in the vertebrate brain - regional distribudon examined by autoradiography. Naunyn Schmiedebergs Arch Pharmacol 340: 486–494

    CAS  Google Scholar 

  228. Waeber C, Hoyer D, Palacios JM (1989) 5-Hydroxytryptamine3 receptors in the human brain: autoradiographic visualization using [3H]ICS 205–930. Neuroscience 31: 393–400

    Google Scholar 

  229. Walters BB, Gillespie SA, Moskowitz MA (1986) Cerebrovascular projecdons from the sphenopalatine and ode ganglia to the middle cerebral artery of the cat. Stroke 17: 488–494

    Article  PubMed  CAS  Google Scholar 

  230. Wepfer JJ (1727) Observationes medico-practicae, de affectibus capitis intemis & extemis. Nunc demum publici juris redditae studio & opera nepotum, Bern- hardini Wepferi et Georgii Mich Wepferi. Ziegleri, Schaffhausen

    Google Scholar 

  231. Weiz FA (Hrsg) (1787) Medizinisch-praktische Beobachtungen von den inneren und äußeren Krankheiten des Kopfs. - Aus dem Lateinischen mit den neuesten Erfahrungen bereichert und herausgegeben von Friedrich August Weiz. Wey- gandsche Buchhandlung, Leipzig

    Google Scholar 

  232. Wilhs T (1672) De anima brutorum quae hominis Vitalis ac sensidva est, exer- citadones duae. Prior physiologica ejusdem naturam, partes, potentias & affectio- nes tradit. Altera pathologica morbus qui ipsam, & sedem ejus primarium, nempe cerebrum & nervosum genus afficiunt, explicat, eorumque therapeias instituit. E Theatro Sheldoniano, Oxford

    Google Scholar 

  233. Wolfson WQ, Graham JR (1949) Development of tolerance to ergot alkaloids in a patient with unusually severe migraine. N Engl J Med 241: 296–298

    Article  PubMed  CAS  Google Scholar 

  234. Woolley DW, Shaw E (1952) Some antimetabolites of serotonin and their possible application to the treatment of hypertension.-Letter to the editor. J Am Chem Soc 74: 2948–2949

    Article  CAS  Google Scholar 

  235. Woolley DW, Shaw E (1953) An antiserotonin which is active when fed. J Pharmacol Exp Ther 108: 87–93

    PubMed  CAS  Google Scholar 

  236. Zimmermann O (1935) Störung der Coronardurchblutung durch Ergotamin. Klin Wochenschr 14: 500–503

    Article  CAS  Google Scholar 

  237. Zgombick JM, Schechter LE, Macci M, Hartig PR, Branchek TA, Weinshank RL (1993) Human gene S31 encodes the pharmacolgically defined serotonin 5-hydroxy tryptamine IE receptor. Mol Pharmacol 42: 180–185

    Google Scholar 

Download references

Authors
  1. Franz Bernhard M. Ensink
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Zentrum Anaesthesiologie, Rettungs- und Intensivmedizin, Universität Göttingen, Robert-Koch-Straße 40, 37075, Göttingen, Deutschland

    Franz Bernhard M. Ensink

  2. Klinik für Neurologie, Universität Kiel, Niemannsweg 147, 24105, Kiel, Deutschland

    Dieter Soyka

Rights and permissions

Reprints and permissions

Copyright information

© 1994 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Ensink, F.B.M. (1994). Vom Mutterkorn zum selektiven Serotoninrezeptoragonisten — Historische Aspekte der Entwicklung eines spezifischen Migränetherapeutikums. In: Ensink, F.B.M., Soyka, D. (eds) Migräne. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-93522-0_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-93522-0_2

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-93523-7

  • Online ISBN: 978-3-642-93522-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation